All HHS Contracts — July 30, 2026

KADIAK LLC (subsidiary of KONIAG, INC.) has outlayed $42.2M of $48.5M on a firm-fixed-price Indian Health Service IT support contract, indicating 87% execution rate and reliable recurring revenue through February 2026. The 'Buy Indian' and 8(a) set-asides limit competition.

CANGENE CORPORATION (Emergent Biosolutions subsidiary) was awarded a $63.3M firm-fixed-price BARDA contract in 2013, but $0 has been outlayed as of the data snapshot. The contract is now expired, suggesting possible termination, non-performance, or data lag.

OSSIUM HEALTH won a $61M (base) BARDA contract for bone marrow cryo-banking to treat acute radiation syndrome, with total potential value of $122M including options. The full-and-open competition win suggests technical superiority in a niche biodefense market.

CANGENE/EMERGENT's $63.3M BARDA contract shows $0 outlayed despite being awarded in 2013 and expiring in 2018. This could indicate contract termination, non-performance, or a data error, but raises material execution concerns for EMERGENT BIOSOLUTIONS.

OSSIUM HEALTH's $61M cost-sharing contract requires the company to share a portion of costs, compressing margins. If BARDA exercises options, total value reaches $122M, but any budget cuts to BARDA's medical countermeasure programs could delay or cancel option exercises.

KADIAK LLC's $48.5M contract represents a significant revenue concentration for KONIAG, INC., as the annual run rate of $8.8M is likely material for the parent company. The contract expires February 2026, creating re-compete risk.

KADIAK LLC's 'Buy Indian' and 8(a) set-aside contract demonstrates a structural competitive advantage for Alaskan Native Corporation-owned small businesses in Indian Health Service IT procurements. This moat could be replicated in future IHS contracts.

OSSIUM HEALTH's $61M BARDA award for radiation countermeasures aligns with NDAA priorities for medical preparedness against CBRN threats. The full-and-open competition win suggests potential for follow-on contracts or expanded scope.

KADIAK LLC's $48.5M IT support contract for Indian Health Service reflects stable civilian agency demand for managed IT services. With $42.2M already outlayed, the contract provides predictable cash flow through early 2026.

Two of three contracts ($124.3M total) are BARDA awards for pharmaceutical R&D and biodefense countermeasures, indicating sustained HHS investment in pandemic preparedness. However, the $63.3M CANGENE contract with zero outlays highlights execution risk in this sector.

KADIAK LLC's 'Buy Indian' and 8(a) set-aside contract for Indian Health Service IT support demonstrates how preferential procurement programs can provide long-term, recurring revenue streams with limited competition.

{"entity" => "EMERGENT BIOSOLUTIONS INC.", "reason" => "The $63.3M CANGENE contract with zero outlays raises questions about BARDA relationship and past performance.", "trigger" => "Emergent Biosolutions' next quarterly filing or SEC disclosure on this contract"}

{"entity" => "OSSIUM HEALTH, INC.", "reason" => "The $61M BARDA cost-sharing contract has $122M potential value if options are exercised, representing significant growth.", "trigger" => "BARDA option exercise announcement or modification"}

{"entity" => "KONIAG, INC.", "reason" => "The $48.5M KADIAK contract expires February 2026; re-compete outcome will determine revenue continuity.", "trigger" => "Indian Health Service solicitation for follow-on IT support contract"}

{"entity" => "BARDA (HHS)", "reason" => "Two contracts totaling $124.3M indicate BARDA is a key funding source; budget cuts or CRs could impact option exercises.", "trigger" => "FY2027 HHS budget request or CR passage"}